You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
Researchers said that the score further may identify patients whose treatment resistance may be overcome with combination strategies targeting certain cells.
If the team is successful in expanding on the results that they reported last month, it could open a new application for the still nascent circulating tumor DNA technology.
The companies initially plan to expand the commercialization of Sophia's DDM analytics platform and Hitachi's digital healthcare technology in certain geographic areas.
With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.
The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.
Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.